Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
Status:
Recruiting
Trial end date:
2023-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find out whether the study drug, LY3537982, is safe and
effective in cancer patients who have a specific genetic mutation (KRAS G12C). Patients must
have already received or were not able to tolerate the standard of care. The study will last
up to approximately 2 years.